Deep vein thrombosis in a patient with lepromatous leprosy receiving thalidomide to treat leprosy reaction. 2013

G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
Servicio de Dermatología, Hospital 12 de Octubre, Madrid España. gisepetiti@hotmail.com

Thalidomide is the treatment of choice for severe or recurrent erythema nodosum leprosum. Its use has been associated with deep vein thrombosis in patients with blood disorders, however, particularly when used in combination with corticosteroids or chemotherapy. We describe a case of deep vein thrombosis in a 43-year-old man with lepromatous leprosy who was being treated with thalidomide and prednisone for a type 2 leprosy reaction (erythema nodosum leprosum); the patient also had transiently positive antiphospholipid antibody results. We stress the importance of considering deep vein thrombosis, a potentially fatal complication, in dermatology patients treated with thalidomide.

UI MeSH Term Description Entries
D007917 Leprostatic Agents Substances that suppress Mycobacterium leprae, ameliorate the clinical manifestations of leprosy, and/or reduce the incidence and severity of leprous reactions. Antileprotic Agents,Leprostatics,Agents, Antileprotic,Agents, Leprostatic
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013792 Thalidomide A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action. Sedoval,Thalomid
D015440 Leprosy, Lepromatous A chronic communicable infection which is a principal or polar form of LEPROSY. This disorder is caused by MYCOBACTERIUM LEPRAE and produces diffuse granulomatous skin lesions in the form of nodules, macules, or papules. The peripheral nerves are involved symmetrically and neural sequelae occur in the advanced stage. Leprosy, Cutaneous,Leprosy, Nodular,Cutaneous Leprosies,Cutaneous Leprosy,Lepromatous Leprosies,Lepromatous Leprosy,Leprosies, Cutaneous,Leprosies, Lepromatous,Leprosies, Nodular,Nodular Leprosies,Nodular Leprosy
D020246 Venous Thrombosis The formation or presence of a blood clot (THROMBUS) within a vein. Deep Vein Thrombosis,Phlebothrombosis,Thrombosis, Deep Vein,Thrombosis, Venous,Deep Venous Thrombosis,Deep-Vein Thrombosis,Deep-Venous Thrombosis,Deep Vein Thromboses,Deep Venous Thromboses,Deep-Vein Thromboses,Deep-Venous Thromboses,Phlebothromboses,Thromboses, Deep Vein,Thromboses, Deep Venous,Thromboses, Deep-Vein,Thromboses, Deep-Venous,Thromboses, Venous,Thrombosis, Deep Venous,Thrombosis, Deep-Vein,Thrombosis, Deep-Venous,Vein Thromboses, Deep,Vein Thrombosis, Deep,Venous Thromboses,Venous Thromboses, Deep,Venous Thrombosis, Deep

Related Publications

G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
September 1967, Archivos argentinos de dermatologia,
G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
January 1984, Indian journal of leprosy,
G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
July 2007, Internal medicine journal,
G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
January 2022, Cureus,
G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
December 2007, Leukemia & lymphoma,
G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
July 1997, Antimicrobial agents and chemotherapy,
G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
September 2002, Blood,
G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
February 2001, Annales de dermatologie et de venereologie,
G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
September 2001, Blood,
G Hebe Petiti-Martin, and M Villar-Buill, and I de la Hera, and L Fuertes, and M Burgués-Calderón, and R Rivera-Díaz, and F Vanaclocha
January 1980, International journal of dermatology,
Copied contents to your clipboard!